Who Generates Higher Gross Profit? Pharming Group N.V. or BioCryst Pharmaceuticals, Inc.

Biotech Giants Battle for Gross Profit Supremacy

__timestampBioCryst Pharmaceuticals, Inc.Pharming Group N.V.
Wednesday, January 1, 20141348600021595165
Thursday, January 1, 2015463610006590427
Friday, January 1, 20162365400011768542
Sunday, January 1, 20172348400092587038
Monday, January 1, 201820182000129203843
Tuesday, January 1, 201944734000165412447
Wednesday, January 1, 202016136000203056430
Friday, January 1, 2021149906000169670071
Saturday, January 1, 2022264233000188060000
Sunday, January 1, 2023326751000220104000
Loading chart...

Unleashing insights

A Tale of Two Biotechs: Gross Profit Showdown

In the competitive world of biotechnology, financial performance is a key indicator of success. Over the past decade, Pharming Group N.V. and BioCryst Pharmaceuticals, Inc. have been vying for dominance in gross profit generation. From 2014 to 2023, Pharming Group N.V. consistently outperformed BioCryst Pharmaceuticals, Inc. in the early years, peaking in 2020 with a gross profit that was nearly 25% higher than its rival. However, the tide turned in 2022 when BioCryst Pharmaceuticals, Inc. surged ahead, achieving a 44% increase in gross profit compared to Pharming Group N.V. by 2023. This shift highlights the dynamic nature of the biotech industry, where strategic decisions and market conditions can rapidly alter financial standings. As we look to the future, the question remains: will BioCryst maintain its lead, or will Pharming reclaim its former glory?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025